Skip to main content

Panitumumab Side Effects

Medically reviewed by Drugs.com. Last updated on May 2, 2025.

Applies to panitumumab: intravenous solution.

Important warnings This medicine can cause some serious health issues

Intravenous route (solution)

Dermatologic toxicities were reported in 90% of patients and were severe in 15% of patients receiving panitumumab monotherapy.

Precautions

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly. Blood tests may be needed to check for unwanted effects.

Using this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant during treatment with this medicine and for 2 months after the last dose. If you think you have become pregnant while using the medicine, tell your doctor right away.

You should not receive this medicine if you are also using oxaliplatin and have mutant KRAS metastatic colorectal cancer or if your KRAS tumor status is unknown.

Some patients who use this medicine develop serious skin problems that may lead to infections that can become life-threatening. Tell your doctor right away if you have skin changes, such as a skin rash, itchiness, skin redness or swelling, dry, peeling skin or fissures, or fingernail changes while using this medicine.

This medicine may cause scarring of the lungs (pulmonary fibrosis), swelling of the lungs (pneumonitis), or interstitial lung disease. These are life-threatening conditions and require immediate medical attention. The symptoms may be similar to the symptoms of lung cancer. Check with your doctor right away if you have new or worsening cough, fever, or trouble breathing.

This medicine may cause infusion-related reactions, which can be life-threatening and require immediate medical attention. Tell your doctor right away if you start to have a fever, chills or shaking, dizziness, trouble breathing, itching or rash, lightheadedness or fainting after receiving this medicine.

Check with your doctor right away if blurred vision, difficulty with reading, or any other change in vision occurs during or after your treatment. Your doctor may want your eyes be checked by an ophthalmologist (eye doctor).

This medicine may cause severe kidney disease in patients who have severe diarrhea and dehydration. This medicine may also increase your risk of having an electrolyte imbalance (eg, low magnesium, potassium, or calcium in the blood). Tell your doctor right away if you start having bloating or swelling of the face, arms, hands, lower legs, ankles, or feet, decreased urination, dizziness, headache, lethargy, muscle cramps or twitching, mood or mental changes, nausea, rapid weight gain, or unusual tiredness or weakness while being treated with this medicine.

Avoid overexposing your skin to sunlight. Always use sunscreen or sun blocking lotions and wear protective clothing and hats while you are receiving this medicine and for 2 months after the last dose.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Serious side effects of panitumumab

Along with its needed effects, panitumumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking panitumumab:

More common side effects

  • anxiety
  • bloating or swelling of the face, arms, hands, lower legs, ankles, or feet
  • chest pain
  • chills
  • confusion
  • constipation
  • convulsions
  • cough
  • decreased urination
  • deep cracks, grooves, or lines in the skin
  • diarrhea
  • difficulty with swallowing
  • discoloration of the fingernails or toenails
  • drowsiness
  • dry mouth, lips, or skin
  • fainting
  • fast or irregular heartbeat
  • fever
  • flushing or redness of the skin
  • increased thirst
  • itching, pain, and swelling of the eyelid
  • itching, skin rash
  • loosening of the fingernails
  • loss of appetite
  • muscle pain or cramps
  • muscle spasms or twitching
  • nausea
  • rapid weight gain
  • rapid, shallow breathing
  • redness or soreness around the fingernails
  • sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • stomach pain
  • sunken eyes
  • swelling or inflammation of the mouth
  • tearing of the eyes
  • tingling of the hands or feet
  • trembling
  • troubled breathing
  • unusual tiredness or weakness
  • unusual weight gain or loss
  • unusually warm skin
  • vomiting

Less common side effects

  • blurred vision
  • burning, dry, or itching eyes
  • discharge from the eyes or excessive tearing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • facial swelling
  • headache
  • hives
  • noisy breathing
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • sweating
  • swelling of the eye, eyelid, or inner lining of the eyelid
  • tightness in the chest

Rare side effects

  • chest discomfort
  • painful breathing
  • quick, shallow breathing
  • slight fever

Incidence not known

  • bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, or warmth at the injection site
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs

For healthcare professionals

Applies to panitumumab: intravenous solution.

Dermatologic adverse events

Gastrointestinal

When used in combination with irinotecan, the incidence and severity of diarrhea is increased. In a study of 19 patients who received panitumumab in combination with irinotecan, 5-fluorouracil, and leucovorin, the incidence of grade 3 or 4 diarrhea was 58% and was fatal in one patient. The combination of panitumumab with leucovorin is not recommended.[Ref]

Metabolic

Median magnesium levels decreased by 0.1 mmol/L. Hypomagnesemia (grade 3 or 4) requiring oral or IV electrolyte repletion occurred in 2% of patients. Hypomagnesemia occurred 6 weeks or longer after the initiation of panitumumab. In some patients, hypomagnesemia was associated with hypocalcemia. Patient's electrolytes should be monitored during and for eight weeks after the completion of panitumumab therapy. Patients should be periodically monitored for hypomagnesemia and accompanying hypocalcemia during the eight weeks after the completion of panitumumab therapy.[Ref]

Respiratory

Panitumumab should be permanently discontinued in patients developing interstitial lung disease, pneumonitis, or lung infiltrates.[Ref]

Ocular

Hypersensitivity

Severe infusion reactions were identified as anaphylactic reaction, bronchospasm, fever, chills, and hypotension. Although fatal infusion reactions have not been reported with panitumumab, fatalities have occurred with other monoclonal antibody products. The infusion should be stopped if a severe infusion reaction occurs. Depending on the severity and/or persistence of the reaction, panitumumab may need to be permanently discontinued.[Ref]

Hematologic

Immunologic

Nervous system

Other

Renal

See also:

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

2. Pharmaceutical Society of Australia (2006) APPGuide online. Australian prescription products guide online. http://www.appco.com.au/appguide/default.asp

3. (2006) "Product Information. Vectibix (panitumumab)." Amgen USA

4. Cerner Multum, Inc. "Australian Product Information."

Further information

Panitumumab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.